Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
RayzeBio, Inc. | 10%+ Owner | Common Stock | 1.86M | $116M | $62.50 | Sep 19, 2023 | Indirect |
Shattuck Labs, Inc. | Director, 10%+ Owner | Common Stock | 5.62M | $59.1M | $10.53 | Mar 28, 2024 | Indirect |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Common Stock | 13.2M | $57.6M | $4.37 | Dec 26, 2023 | Indirect |
IGM Biosciences, Inc. | Director, 10%+ Owner | Non-Voting Common Stock | 7.2M | $47.5M | $6.60 | Feb 28, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Common Shares, par value CHF 0.08 per share | 15.7M | $44M | $2.81 | Jul 1, 2024 | Indirect |
Absci Corp | Director | Common Stock | 8.26M | $41.1M | $4.98 | Jun 12, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Pre-Funded Warrants | 8.16M | $39.3M | $4.81 | May 8, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Common Shares, par value CHF 0.08 per share | 13M | $36.5M | $2.81 | Jul 1, 2024 | Direct |
IGM Biosciences, Inc. | Director, 10%+ Owner | Common Stock | 3.08M | $35.6M | $11.54 | Sep 30, 2024 | Indirect |
Entrada Therapeutics, Inc. | 10%+ Owner | Common Stock | 1.95M | $31.3M | $15.99 | Nov 2, 2021 | Indirect |
Zymeworks Inc. | 10%+ Owner | Common Stock, par value $0.00001 per share | 6.08M | $30.6M | $5.03 | Oct 13, 2022 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Pre-Funded Warrants | 6.11M | $29.4M | $4.81 | May 8, 2024 | Direct |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 3.89M | $21.4M | $5.50 | Mar 21, 2024 | Indirect |
Verve Therapeutics, Inc. | 10%+ Owner | Common Stock | 1.94M | $19.4M | $10.00 | Jun 21, 2021 | Indirect |
Adagio Therapeutics, Inc. | 10%+ Owner | Common Stock | 3.39M | $13.4M | $3.95 | Aug 10, 2021 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Cash-settled Swaps | 108K | $364K | $3.38 | Feb 7, 2024 | Direct |
FATE THERAPEUTICS INC | Director, 10%+ Owner | Stock Option (Right to Buy) | 40K | $109K | $2.73 | Jun 7, 2024 | Indirect |
ADC Therapeutics SA | 10%+ Owner | Cash-settled Swaps | 11.2K | $37.8K | $3.38 | Feb 2, 2024 | Indirect |
Augmedix, Inc. | Director, 10%+ Owner | Common Stock | 0 | $0 | $2.35 | Oct 2, 2024 | Direct |
Augmedix, Inc. | Director, 10%+ Owner | Common Stock | 0 | $0 | $2.35 | Oct 2, 2024 | Indirect |
Science 37 Holdings, Inc. | Former 10% Owner and Director | Common Stock | 0 | $0 | $5.75 | Mar 12, 2024 | Indirect |
MedAvail Holdings, Inc. | Director, 10%+ Owner | Series A Warrants to Purchase Common Stock | 38.9M | Jun 16, 2023 | Direct | ||
MedAvail Holdings, Inc. | Director, 10%+ Owner | Series A Warrants to Purchase Common Stock | 38.9M | Jun 16, 2023 | Indirect | ||
Shattuck Labs, Inc. | Director, 10%+ Owner | Pre-Funded Warrant to Purchase Common Stock | 3.1M | Dec 21, 2023 | Indirect | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrant | 1.09M | Nov 20, 2023 | Direct | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrant | 1.09M | Nov 20, 2023 | Indirect | ||
Absci Corp | Director | Stock Option (Right to Buy) | 36.3K | Jun 12, 2024 | Indirect | ||
IGM Biosciences, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 29.4K | Mar 12, 2024 | Indirect | ||
Shattuck Labs, Inc. | Director, 10%+ Owner | Stock Option (Right to Buy) | 27.7K | Jun 21, 2024 | Indirect | ||
Adagio Therapeutics, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Aug 10, 2021 | Indirect | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrants | 0 | Oct 2, 2024 | Direct | ||
Augmedix, Inc. | Director, 10%+ Owner | Breakeven Warrants | 0 | Oct 2, 2024 | Indirect | ||
Augmedix, Inc. | Director, 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 0 | Oct 2, 2024 | Direct | ||
Augmedix, Inc. | Director, 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 0 | Oct 2, 2024 | Indirect | ||
Entrada Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Nov 2, 2021 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series D Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
Science 37 Holdings, Inc. | Former 10% Owner and Director | Earn-Out Right | 0 | Mar 12, 2024 | Indirect | ||
Science 37 Holdings, Inc. | Former 10% Owner and Director | Stock Options (Right to Buy) | 0 | Mar 12, 2024 | Indirect | ||
Verve Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Jun 21, 2021 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AUGX | Augmedix, Inc. | Oct 2, 2024 | 7 | -$75.4M | 4 | Oct 4, 2024 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 30, 2024 | 1 | $0 | 4 | Oct 2, 2024 | Director, 10%+ Owner |
ADCT | ADC Therapeutics SA | Jul 1, 2024 | 2 | $2.25M | 4 | Jul 3, 2024 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 28, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 21, 2024 | 1 | $0 | 4 | Jun 21, 2024 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Jun 14, 2024 | 1 | $0 | 4 | Jun 18, 2024 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 12, 2024 | 2 | $0 | 4 | Jun 14, 2024 | Director |
FATE | FATE THERAPEUTICS INC | Jun 7, 2024 | 1 | $0 | 4 | Jun 11, 2024 | Director, 10%+ Owner |
ADCT | ADC Therapeutics SA | May 8, 2024 | 2 | $68.7M | 4 | May 10, 2024 | 10%+ Owner |
STTK | Shattuck Labs, Inc. | Mar 28, 2024 | 1 | $0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 28, 2024 | 2 | $0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Mar 21, 2024 | 1 | $20M | 4 | Mar 25, 2024 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Mar 15, 2024 | 1 | $0 | 4 | Mar 19, 2024 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 12, 2024 | 1 | $0 | 4 | Mar 14, 2024 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Mar 12, 2024 | 3 | -$5.85M | 4 | Mar 13, 2024 | Former 10% Owner and Director |
ABSI | Absci Corp | Mar 1, 2024 | 1 | $1M | 4 | Mar 5, 2024 | Director |
IGMS | IGM Biosciences, Inc. | Feb 28, 2024 | 2 | $0 | 4 | Mar 1, 2024 | Director, 10%+ Owner |
ADCT | ADC Therapeutics SA | Jan 3, 2024 | 22 | -$167K | 4 | Feb 9, 2024 | 10%+ Owner |
ADCT | ADC Therapeutics SA | Jan 2, 2024 | 0 | $0 | 3 | Feb 9, 2024 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 29, 2023 | 1 | $0 | 4 | Jan 3, 2024 | Director |
FATE | FATE THERAPEUTICS INC | Dec 26, 2023 | 3 | $166K | 4 | Dec 28, 2023 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Dec 21, 2023 | 1 | $0 | 4 | Dec 26, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Dec 15, 2023 | 1 | $0 | 4 | Dec 19, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Nov 20, 2023 | 4 | $6M | 4 | Nov 22, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 29, 2023 | 1 | $0 | 4 | Oct 3, 2023 | Director |
RYZB | RayzeBio, Inc. | Sep 19, 2023 | 6 | $0 | 4 | Sep 21, 2023 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | 10%+ Owner |
AUGX | Augmedix, Inc. | Aug 31, 2023 | 1 | $10K | 4 | Sep 5, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Jul 13, 2023 | 1 | $0 | 4 | Jul 17, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 29, 2023 | 5 | $0 | 4 | Jul 3, 2023 | Director |
IGMS | IGM Biosciences, Inc. | Jun 26, 2023 | 1 | $22.5M | 4 | Jun 28, 2023 | Director |
MDVL | MedAvail Holdings, Inc. | Jun 16, 2023 | 2 | $0 | 4 | Jun 21, 2023 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 14, 2023 | 1 | $0 | 4 | Jun 16, 2023 | Director |
FATE | FATE THERAPEUTICS INC | Jun 6, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | May 26, 2023 | 1 | $0 | 4 | May 31, 2023 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | May 11, 2023 | 1 | $125K | 4 | May 15, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | May 2, 2023 | 3 | -$15M | 4 | May 4, 2023 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Apr 20, 2023 | 2 | $1.71M | 4 | Apr 21, 2023 | Director, 10%+ Owner |
AUGX | Augmedix, Inc. | Apr 19, 2023 | 2 | $7M | 4 | Apr 21, 2023 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Apr 13, 2023 | 12 | -$1.61M | 4 | Apr 17, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Apr 4, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 31, 2023 | 1 | $0 | 4 | Apr 4, 2023 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Mar 9, 2023 | 2 | $25M | 4 | Mar 13, 2023 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 30, 2022 | 1 | $0 | 4 | Jan 4, 2023 | Director, 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 1 | $153K | 4/A | Oct 18, 2022 | 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 0 | $0 | 3 | Oct 17, 2022 | 10%+ Owner |
ZYME | Zymeworks Inc. | Oct 13, 2022 | 0 | $0 | 3 | Oct 17, 2022 | 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Oct 3, 2022 | 6 | $0 | 4 | Oct 5, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 30, 2022 | 1 | $0 | 4 | Oct 4, 2022 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Jul 1, 2022 | 4 | $18.1M | 4 | Jul 6, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 30, 2022 | 1 | $0 | 4 | Jul 5, 2022 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Jun 13, 2022 | 2 | $0 | 4 | Jun 15, 2022 | Director, 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Jun 9, 2022 | 2 | $0 | 4 | Jun 13, 2022 | Director, 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
ABSI | Absci Corp | Jun 8, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | May 23, 2022 | 1 | $125K | 4 | May 25, 2022 | Director, 10%+ Owner |
MDVL | MedAvail Holdings, Inc. | Apr 4, 2022 | 2 | $15M | 4 | Apr 6, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 31, 2022 | 2 | $60M | 4 | Apr 4, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Mar 12, 2022 | 1 | $0 | 4 | Mar 15, 2022 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Dec 31, 2021 | 1 | $0 | 4 | Jan 4, 2022 | Director, 10%+ Owner |
TRDA | Entrada Therapeutics, Inc. | Nov 2, 2021 | 3 | $20M | 4 | Nov 4, 2021 | 10%+ Owner |
AUGX | Augmedix, Inc. | Oct 28, 2021 | 1 | $6.5M | 4/A | Apr 21, 2023 | Director, 10%+ Owner |
TRDA | Entrada Therapeutics, Inc. | Oct 28, 2021 | 0 | $0 | 3 | Oct 28, 2021 | 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 7, 2021 | 1 | $0 | 4 | Oct 12, 2021 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 6, 2021 | 1 | $0 | 4/A | Oct 18, 2021 | Director, 10%+ Owner |
SNCE | Science 37 Holdings, Inc. | Oct 6, 2021 | 0 | $0 | 3 | Oct 8, 2021 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Sep 30, 2021 | 1 | $0 | 4 | Oct 4, 2021 | Director, 10%+ Owner |
IVVD | Adagio Therapeutics, Inc. | Aug 10, 2021 | 3 | $25M | 4 | Aug 12, 2021 | 10%+ Owner |
IVVD | Adagio Therapeutics, Inc. | Aug 5, 2021 | 0 | $0 | 3 | Aug 5, 2021 | 10%+ Owner |
ABSI | Absci Corp | Jul 26, 2021 | 5 | $5M | 4 | Jul 28, 2021 | Director |
ABSI | Absci Corp | Jul 21, 2021 | 0 | $0 | 3 | Jul 21, 2021 | Director, 10%+ Owner |
IGMS | IGM Biosciences, Inc. | Jun 30, 2021 | 1 | $0 | 4 | Jul 2, 2021 | Director, 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 21, 2021 | 3 | $20M | 4 | Jun 23, 2021 | 10%+ Owner |
STTK | Shattuck Labs, Inc. | Jun 19, 2021 | 1 | $0 | 4 | Jun 22, 2021 | Director, 10%+ Owner |
VERV | Verve Therapeutics, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | 10%+ Owner |
FATE | FATE THERAPEUTICS INC | Jun 2, 2021 | 2 | $0 | 4 | Jun 4, 2021 | Director, 10%+ Owner |